BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bermudez-Lopez M, Forne C, Amigo N, Bozic M, Arroyo D, Bretones T, Alonso N, Cambray S, Del Pino MD, Mauricio D, Gorriz JL, Fernandez E, Valdivielso JM. An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients. Expert Opin Ther Targets 2019;23:619-30. [PMID: 31100024 DOI: 10.1080/14728222.2019.1620206] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
Number Citing Articles
1 Loutradis C, Sarafidis PA, Ortiz A, Ferro CJ. Is Our Increasing Understanding of PCSK9 and Lp(a) Metabolism the Key to Unlocking the Paradox of Statins Ineffectiveness in Reducing Cardiovascular Events in Advanced CKD? SN Compr Clin Med 2022;4:145. [DOI: 10.1007/s42399-022-01242-w] [Reference Citation Analysis]
2 Wang J, Sun Q, An Y, Liu J, Leng S, Wang G. The association of remnant cholesterol (RC) and interaction between RC and diabetes on the subsequent risk of hypertension. Front Endocrinol 2022;13:951635. [DOI: 10.3389/fendo.2022.951635] [Reference Citation Analysis]
3 Šuran D, Blažun Vošner H, Završnik J, Kokol P, Sinkovič A, Kanič V, Kokol M, Naji F, Završnik T. Lipoprotein(a) in Cardiovascular Diseases: Insight From a Bibliometric Study. Front Public Health 2022;10:923797. [DOI: 10.3389/fpubh.2022.923797] [Reference Citation Analysis]
4 Goicoechea M, Álvarez V, Segarra A, Polaina M, Martín-reyes G, Robles NR, Escudero V, Orellana C, Bea Granell S, de Juan-ribera J, Fernández Lucas M, Graña JM, Reque J, Sánchez Hernández R, Villamayor S, Górriz JL. Lipid profile of patients treated with evolocumab in Spanish hospital nephrology units (RETOSS NEFRO). Nefrología (English Edition) 2022. [DOI: 10.1016/j.nefroe.2022.05.005] [Reference Citation Analysis]
5 Chen S, Chen J, Li S, Guo F, Li A, Wu H, Chen J, Pan Q, Liao S, Liu HF, Pan Q. High-Fat Diet-Induced Renal Proximal Tubular Inflammatory Injury: Emerging Risk Factor of Chronic Kidney Disease. Front Physiol 2021;12:786599. [PMID: 34950058 DOI: 10.3389/fphys.2021.786599] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Bermudez-Lopez M, Perpiñan H, Amigo N, Castro E, Alonso N, Mauricio D, Fernandez E, Valdivielso JM. Advanced lipoprotein parameters could better explain atheromatosis in non-diabetic chronic kidney disease patients. Clin Kidney J 2021;14:2591-9. [PMID: 34950470 DOI: 10.1093/ckj/sfab113] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Yan P, Xu Y, Miao Y, Bai X, Wu Y, Tang Q, Zhang Z, Yang J, Wan Q. Association of remnant cholesterol with chronic kidney disease in middle-aged and elderly Chinese: a population-based study. Acta Diabetol 2021;58:1615-25. [PMID: 34181081 DOI: 10.1007/s00592-021-01765-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
8 Chen CH, Ke GM, Lin PC, Lin KD. Therapeutic DNA vaccine encoding CEMIP (KIAA1199) ameliorates kidney fibrosis in obesity through inhibiting the Wnt/β-catenin pathway. Biochim Biophys Acta Gen Subj 2021;1865:130019. [PMID: 34582938 DOI: 10.1016/j.bbagen.2021.130019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Theofilis P, Vordoni A, Koukoulaki M, Vlachopanos G, Kalaitzidis RG. Dyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives. Am J Nephrol 2021;52:693-701. [PMID: 34569479 DOI: 10.1159/000518456] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Goicoechea M, Álvarez V, Segarra A, Polaina M, Martín-Reyes G, Robles NR, Escudero V, Orellana C, Bea Granell S, de Juan-Ribera J, Fernández Lucas M, Graña JM, Reque J, Sánchez Hernández R, Villamayor S, Górriz JL. Lipid profile of patients treated with evolocumab in Spanish hospital nephrology units (RETOSS NEFRO). Nefrologia 2021:S0211-6995(21)00133-8. [PMID: 34389184 DOI: 10.1016/j.nefro.2021.06.004] [Reference Citation Analysis]
11 Lee CK, Liao CW, Meng SW, Wu WK, Chiang JY, Wu MS. Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis. Biomedicines 2021;9:985. [PMID: 34440189 DOI: 10.3390/biomedicines9080985] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
12 Kajingulu FM, Lepira FB, Nkodila AN, Makulo JR, Mokoli VM, Ekulu PM, Bukabau JB, Nlandu YM, Longo AL, Nseka NM, Sumaili EK. Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels Predict Future Cardiovascular Event Risks in Hemodialyzed Black African Patients. Rambam Maimonides Med J 2021;12. [PMID: 34270402 DOI: 10.5041/RMMJ.10443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Dounousi E, Tellis C, Pavlakou P, Duni A, Liakopoulos V, Mark PB, Papagianni A, Tselepis AD. Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of Nondialysis Chronic Kidney Disease Patients. Oxid Med Cell Longev 2021;2021:6677012. [PMID: 34336112 DOI: 10.1155/2021/6677012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
14 Burlacu A, Iftene A, Popa IV, Crisan-Dabija R, Brinza C, Covic A. Computational Models Used to Predict Cardiovascular Complications in Chronic Kidney Disease Patients: A Systematic Review. Medicina (Kaunas) 2021;57:538. [PMID: 34072159 DOI: 10.3390/medicina57060538] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Ma L, Wang S, Zhao H, Yu M, Deng X, Jiang Y, Cao Y, Li P, Niu W. Susceptibility of ApoB and PCSK9 Genetic Polymorphisms to Diabetic Kidney Disease Among Chinese Diabetic Patients. Front Med (Lausanne) 2021;8:659188. [PMID: 33889589 DOI: 10.3389/fmed.2021.659188] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Gorriz JL, Arroyo D, D'Marco L, Torra R, Tomás P, Puchades MJ, Panizo N, Pantoja J, Montomoli M, Llisterri JL, Pallares-Carratalá V, Valdivielso JM. Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease. BMC Nephrol 2021;22:110. [PMID: 33765945 DOI: 10.1186/s12882-021-02313-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Pallarés-Carratalá V, Quesada JA, Orozco-Beltrán D, Amigó-Grau N, Lopez-Pineda A, Fernández Giménez A, Gil-Guillén VF, Correig X, Masana L, Monleón D, Redón J, Pascual R, Carratalá-Munuera C. Analysis of LDL and HDL size and number by nuclear magnetic resonance in a healthy working population: The LipoLab Study. Int J Clin Pract 2021;75:e13610. [PMID: 32648987 DOI: 10.1111/ijcp.13610] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Banik SD, Cardoza RH, González RMM, Solis ALG. Fasting plasma glucose, lipid ratios, and atherogenic coefficient are the risk factors for hypertension in chronic kidney disease patients on hemodialysis: A report from the Regional High Speciality Hospital of Peninsular Yucatan, Mexico. Anthropological Review 2020;83:251-60. [DOI: 10.2478/anre-2020-0019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Cambray S, Ibarz M, Bermudez-Lopez M, Marti-Antonio M, Bozic M, Fernandez E, Valdivielso JM. Magnesium Levels Modify the Effect of Lipid Parameters on Carotid Intima Media Thickness. Nutrients 2020;12:E2631. [PMID: 32872319 DOI: 10.3390/nu12092631] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
20 Li B, Wang A, Wang Y, Li L, Li B, Yang Z, Zhou X, Gao Z, Tang X, Yan L, Wan Q, Wang W, Qin G, Chen L, Ning G, Mu Y. A study on the correlation between remnant cholesterol and urinary albumin to creatinine ratio in Chinese community adults: A report from the REACTION study. J Diabetes 2020;12:870-80. [PMID: 32500969 DOI: 10.1111/1753-0407.13076] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Carmona-Maurici J, Amigó N, Cuello E, Bermúdez M, Baena-Fustegueras JA, Peinado-Onsurbe J, Pardina E. Bariatric surgery decreases oxidative stress and protein glycosylation in patients with morbid obesity. Eur J Clin Invest 2020;50:e13320. [PMID: 32535887 DOI: 10.1111/eci.13320] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
22 Simeoni M, Borrelli S, Garofalo C, Fuiano G, Esposito C, Comi A, Provenzano M. Atherosclerotic-nephropathy: an updated narrative review. J Nephrol 2021;34:125-36. [PMID: 32270411 DOI: 10.1007/s40620-020-00733-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
23 Yuan Q, Zhang H, Deng T, Tang S, Yuan X, Tang W, Xie Y, Ge H, Wang X, Zhou Q, Xiao X. Role of Artificial Intelligence in Kidney Disease. Int J Med Sci 2020;17:970-84. [PMID: 32308551 DOI: 10.7150/ijms.42078] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
24 Fernandez-Prado R, Perez-Gomez MV, Ortiz A. Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease. Clin Kidney J 2020;13:753-7. [PMID: 33123354 DOI: 10.1093/ckj/sfaa001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
25 Valdivielso JM, Rodríguez-Puyol D, Pascual J, Barrios C, Bermúdez-López M, Sánchez-Niño MD, Pérez-Fernández M, Ortiz A. Atherosclerosis in Chronic Kidney Disease: More, Less, or Just Different? Arterioscler Thromb Vasc Biol 2019;39:1938-66. [PMID: 31412740 DOI: 10.1161/ATVBAHA.119.312705] [Cited by in Crossref: 88] [Cited by in F6Publishing: 96] [Article Influence: 29.3] [Reference Citation Analysis]